公开(公告)号：US20150209364A1

公开(公告)日：2015-07-30

申请号：US14677271

申请日：2015-04-02

申请人： Johnpro Biotech Inc.

发明人： Yu-Shan Wang ,  Yi-Chun Huang ,  Chao-Chun Chang ,  Kwan-Hwa Chi ,  Pei-Ru Liao

IPC分类号： A61K31/5377 ,  A61K31/4706 ,  A61K31/436

CPC分类号： A61K31/5377 ,  A61K31/436 ,  A61K31/4706 ,  A61K31/517 ,  A61K2300/00

摘要： Disclosed herein is a method for enhancing the susceptibility of a subject having epidermoid carcinoma toward a tyrosine kinase inhibitor. The method includes administering to the subject an effective amount of a targeted therapy sensitizer and an effective amount of gefitinib. According to various embodiments of the present disclosure, the targeted therapy sensitizer consists of rapamycin and a substituted quinoline, such as chloroquine. Also included herein is a pharmaceutical composition that includes an effective amount of gefitinib, an effective amount of a targeted therapy sensitizer for synergistically improving or enhancing the efficacy of the gefitinib for treating epidermoid carcinoma in a subject in need thereof, and a pharmaceutically acceptable excipient.

摘要翻译： 本文公开了一种增强具有表皮样癌的受试者对酪氨酸激酶抑制剂的敏感性的方法。 该方法包括向受试者施用有效量的靶向治疗敏化剂和有效量的吉非替尼。 根据本公开的各种实施方案，靶向治疗敏化剂由雷帕霉素和取代的喹啉如氯喹组成。 本文还包括药物组合物，其包含有效量的吉非替尼，有效量的用于协同改善或增强吉非他尼用于治疗有需要的受试者的表皮样癌的功效的靶向治疗敏化剂和药学上可接受的赋形剂。

公开(公告)号：US20200009127A1

公开(公告)日：2020-01-09

申请号：US16490892

申请日：2017-03-08

申请人： Johnpro Biotech Inc.

发明人： Kwan-Hwa CHI ,  Yu-Shan WANG ,  Yi-Chun HUANG ,  Hsin-Chien CHIANG

IPC分类号： A61K31/47 ,  A61K31/436 ,  A61K38/22 ,  A61K31/573 ,  A61K39/395 ,  A61P35/00

摘要： Disclosed herein are uses of a mammalian target of rapamycin (mTOR) inhibitor and chloroquine or analogue thereof in the manufacture of a medicament for treating cancer patients who are not responsive to a hormone therapy and an immunotherapy. In particular, the medicament is used during the hormone therapy and the immunotherapy to sensitize the patients to the hormone therapy and the immunotherapy.

公开(公告)号：US20200163995A1

公开(公告)日：2020-05-28

申请号：US16636907

申请日：2018-07-23

申请人： Johnpro Biotech Inc.

发明人： Kwan-Hwa CHI ,  Yu-Shan WANG ,  Yi-Chun HUANG ,  Hsin-Chien CHIANG

IPC分类号： A61K35/17 ,  A61K38/17 ,  A61K31/706 ,  A61K31/165 ,  A61K31/201 ,  A61K31/19 ,  A61P35/00

摘要： Disclosed herein is a pharmaceutical kit for treating cancers. The present pharmaceutical kit comprises an agent and an engineered natural killer cell. The agent is capable of increasing a tumor-associated antigen expression in cancer cells, which can then be targeted and destroyed by the engineered natural killer cell having a tumor-associated antigen-specific chimeric antigen receptor. Also disclosure herein is the uses of the present pharmaceutical kit for the treatment of cancers.

公开(公告)号：US20190183798A1

公开(公告)日：2019-06-20

申请号：US16309101

申请日：2016-06-17

申请人： Johnpro Biotech Inc.

发明人： Kwan-Hwa CHI ,  Yu-Shan WANG ,  Hsin-Chien CHIANG ,  Cheng-Chung HUANG

IPC分类号： A61K9/127 ,  A61N5/10 ,  A61N1/40

CPC分类号： A61K9/127 ,  A61K9/0019 ,  A61K31/704 ,  A61N1/40 ,  A61N1/403 ,  A61N5/10

摘要： A method of treating a subject having or suspected of having a solid tumor, comprises administering to the subject an effective amount of a liposome-encapsulated drug, and applying an amplitude-modulated (AM) radiofrequency radiation to the solid tumor.

公开(公告)号：US11285143B2

公开(公告)日：2022-03-29

申请号：US16490892

申请日：2017-03-08

申请人： Johnpro Biotech Inc.

发明人： Kwan-Hwa Chi ,  Yu-Shan Wang ,  Yi-Chun Huang ,  Hsin-Chien Chiang

IPC分类号： A61K31/47 ,  A61P35/00 ,  A61K31/436 ,  A61K31/573 ,  A61K38/22 ,  A61K39/395

摘要： Disclosed herein are uses of a mammalian target of rapamycin (mTOR) inhibitor and chloroquine or analogue thereof in the manufacture of a medicament for treating cancer patients who are not responsive to a hormone therapy and an immunotherapy. In particular, the medicament is used during the hormone therapy and the immunotherapy to sensitize the patients to the hormone therapy and the immunotherapy.

公开(公告)号：US20210015769A1

公开(公告)日：2021-01-21

申请号：US16618161

申请日：2017-05-31

申请人： Johnpro Biotech Inc.

发明人： Kwan-Hwa CHI ,  Yu-Shan WANG ,  Hsin-Chien CHIANG ,  Kai-Chung CHENG

IPC分类号： A61K31/155 ,  A61K31/19 ,  A61P17/02 ,  A61P29/00 ,  A61K9/00

摘要： Disclosed herein are compositions and methods for the treatment of conditions induced by chronic inflammation. According to some embodiments, the compositions and methods involve the use of metformin and sodium butyrate in the treatment of conditions induced by chronic inflammation.

公开(公告)号：US20170246190A1

公开(公告)日：2017-08-31

申请号：US15519559

申请日：2015-10-21

申请人： Johnpro Biotech Inc.

发明人： Pei-Ru LIAO ,  Kwan-Hwa CHI

IPC分类号： A61K31/575 ,  A61K31/4745 ,  A61K36/28 ,  A61K31/353

CPC分类号： A61K31/575 ,  A61K9/209 ,  A61K31/353 ,  A61K31/4745 ,  A61K36/28 ,  A61K2300/00

摘要： Disclosed herein are methods and formulation for enhancing oral availability of CPT-11 during cancer therapy while at the same time, reducing its gastrointestinal (GI) toxicity, thus the methods and formulations as disclosed herein may augment the efficacy of cancer therapy.

公开(公告)号：US11382878B2

公开(公告)日：2022-07-12

申请号：US16618161

申请日：2017-05-31

申请人： Johnpro Biotech Inc.

发明人： Kwan-Hwa Chi ,  Yu-Shan Wang ,  Hsin-Chien Chiang ,  Kai-Chung Cheng

IPC分类号： A61K31/155 ,  A61K31/19 ,  A61P29/00 ,  A61P17/02 ,  A61P17/16 ,  A61K9/00

摘要： Disclosed herein are compositions and methods for the treatment of conditions induced by chronic inflammation. According to some embodiments, the compositions and methods involve the use of metformin and sodium butyrate in the treatment of conditions induced by chronic inflammation.

公开(公告)号：US09913816B2

公开(公告)日：2018-03-13

申请号：US15361079

申请日：2016-11-25

申请人： Johnpro Biotech Inc.

发明人： Kwan-Hwa Chi ,  Yu-Shan Wang ,  Chao-Chun Chang

IPC分类号： A61K31/155 ,  A61K31/20 ,  A61K31/19

CPC分类号： A61K31/19 ,  A61K31/155 ,  A61K2300/00

摘要： A method for using metformin and sodium butyrate in combination to treat a cancer patient with K-ras mutation is disclosed. When administering the pharmaceutical composition to a cancer patient, Metformin and sodium butyrate offer cooperatively therapeutic efficacy. The present invention also discloses a pharmaceutical composition and a pharmaceutical kit containing both aforementioned. The application of the method, the pharmaceutical composition and the pharmaceutical kit of the present invention are advantageous for improving the treatment effect to cancer patients with K-ras mutation.

公开(公告)号：US20170071887A1

公开(公告)日：2017-03-16

申请号：US15361079

申请日：2016-11-25

申请人： Johnpro Biotech Inc.

发明人： Kwan-Hwa CHI ,  Yu-Shan WANG ,  Chao-Chun CHANG

IPC分类号： A61K31/19 ,  A61K31/155

CPC分类号： A61K31/19 ,  A61K31/155 ,  A61K2300/00

摘要： A method for using metformin and sodium butyrate in combination to treat a cancer patient with K-ras mutation is disclosed. When administering the pharmaceutical composition to a cancer patient, Metformin and sodium butyrate offer cooperatively therapeutic efficacy. The present invention also discloses a pharmaceutical composition and a pharmaceutical kit containing both aforementioned. The application of the method, the pharmaceutical composition and the pharmaceutical kit of the present invention are advantageous for improving the treatment effect to cancer patients with K-ras mutation.

摘要翻译： 公开了将二甲双胍和丁酸钠组合用于治疗患有K-ras突变的癌症患者的方法。 当向癌症患者施用药物组合物时，二甲双胍和丁酸钠提供协同治疗功效。 本发明还公开了含有上述两者的药物组合物和药物试剂盒。 本发明的方法，药物组合物和药物试剂盒的应用对于改善对K-ras突变的癌症患者的治疗效果是有利的。